Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Apparent CB1 Receptor Rimonabant Affinity Estimates: Combination with THC and Synthetic Cannabinoids in the Mouse In Vivo Triad Model.

Grim TW, Morales AJ, Thomas BF, Wiley JL, Endres GW, Negus SS, Lichtman AH.

J Pharmacol Exp Ther. 2017 Jul;362(1):210-218. doi: 10.1124/jpet.117.240192. Epub 2017 Apr 25.

PMID:
28442584
2.

Stratification of Cannabinoid 1 Receptor (CB1R) Agonist Efficacy: Manipulation of CB1R Density through Use of Transgenic Mice Reveals Congruence between In Vivo and In Vitro Assays.

Grim TW, Morales AJ, Gonek MM, Wiley JL, Thomas BF, Endres GW, Sim-Selley LJ, Selley DE, Negus SS, Lichtman AH.

J Pharmacol Exp Ther. 2016 Nov;359(2):329-339. Epub 2016 Aug 17.

3.

Quantitative measurement of acetyl fentanyl and acetyl norfentanyl in human urine by LC-MS/MS.

Patton AL, Seely KA, Pulla S, Rusch NJ, Moran CL, Fantegrossi WE, Knight LD, Marraffa JM, Kennedy PD, James LP, Endres GW, Moran JH.

Anal Chem. 2014 Feb 4;86(3):1760-6. doi: 10.1021/ac4036197. Epub 2014 Jan 15.

PMID:
24354295
4.

Forensic investigation of K2, Spice, and "bath salt" commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds.

Seely KA, Patton AL, Moran CL, Womack ML, Prather PL, Fantegrossi WE, Radominska-Pandya A, Endres GW, Channell KB, Smith NH, McCain KR, James LP, Moran JH.

Forensic Sci Int. 2013 Dec 10;233(1-3):416-22. doi: 10.1016/j.forsciint.2013.10.002. Epub 2013 Oct 14.

PMID:
24314548
5.

Targeted metabolomic approach for assessing human synthetic cannabinoid exposure and pharmacology.

Patton AL, Seely KA, Chimalakonda KC, Tran JP, Trass M, Miranda A, Fantegrossi WE, Kennedy PD, Dobrowolski P, Radominska-Pandya A, McCain KR, James LP, Endres GW, Moran JH.

Anal Chem. 2013 Oct 1;85(19):9390-9. doi: 10.1021/ac4024704. Epub 2013 Sep 12.

PMID:
23987522
6.

Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.

Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, James LP, Hollenberg PF, Prather PL, Radominska-Pandya A, Moran JH.

Drug Metab Dispos. 2012 Nov;40(11):2174-84. doi: 10.1124/dmd.112.047530. Epub 2012 Aug 17.

7.

A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors.

Seely KA, Brents LK, Radominska-Pandya A, Endres GW, Keyes GS, Moran JH, Prather PL.

Chem Res Toxicol. 2012 Apr 16;25(4):825-7. doi: 10.1021/tx3000472. Epub 2012 Mar 15.

8.

Solid-phase extraction and quantitative measurement of omega and omega-1 metabolites of JWH-018 and JWH-073 in human urine.

Chimalakonda KC, Moran CL, Kennedy PD, Endres GW, Uzieblo A, Dobrowolski PJ, Fifer EK, Lapoint J, Nelson LS, Hoffman RS, James LP, Radominska-Pandya A, Moran JH.

Anal Chem. 2011 Aug 15;83(16):6381-8. doi: 10.1021/ac201377m. Epub 2011 Jul 27.

9.

Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine.

Moran CL, Le VH, Chimalakonda KC, Smedley AL, Lackey FD, Owen SN, Kennedy PD, Endres GW, Ciske FL, Kramer JB, Kornilov AM, Bratton LD, Dobrowolski PJ, Wessinger WD, Fantegrossi WE, Prather PL, James LP, Radominska-Pandya A, Moran JH.

Anal Chem. 2011 Jun 1;83(11):4228-36. doi: 10.1021/ac2005636. Epub 2011 May 6.

10.

Synthesis of dideoxymycobactin antigens presented by CD1a reveals T cell fine specificity for natural lipopeptide structures.

Young DC, Kasmar A, Moraski G, Cheng TY, Walz AJ, Hu J, Xu Y, Endres GW, Uzieblo A, Zajonc D, Costello CE, Miller MJ, Moody DB.

J Biol Chem. 2009 Sep 11;284(37):25087-96. doi: 10.1074/jbc.M109.000802. Epub 2009 Jul 15.

11.

Pathologic effects of intracavitary irradiation with Californium-252.

Sullivan MF, Beamer JL, Cross FT, Lund JE, Mahony TD, Endres GW, Buschbom RL.

Int J Radiat Oncol Biol Phys. 1980 Dec;6(12):1613-27. No abstract available.

PMID:
7239979
12.

Dose to the GI tract from ingested insoluble beta emitters.

Cross FT, Endres GW, Sullivan MF.

Radiat Res. 1978 Jan;73(1):37-50. No abstract available.

PMID:
622461
13.

The Hanford thermoluminescent multipurpose dosimeter.

Kocher LF, Nichols LL, Endres GW, Shipler DB, Haverfield AJ.

Health Phys. 1973 Dec;25(6):567-73. No abstract available.

PMID:
4784266
14.

An intrauterine dosimeter.

Parker HM, Endres GW, Wheeler RG.

Health Phys. 1972 Sep;23(3):389-90. No abstract available.

PMID:
4642961
15.

Thermoluminescence personnel dosimetry at Hanford.

Kathren RL, Kocher LF, Endres GW.

Am Ind Hyg Assoc J. 1971 Apr;32(4):230-4. No abstract available.

PMID:
5094035
16.

Thermoluminescence personnel dosimetry at Hanford. II. Energy dependence and application of TLD materials in operational health physics.

Endres GW, Kathren RL, Kocher LF.

Health Phys. 1970 Jun;18(6):665-72. No abstract available.

PMID:
5514669
17.

Thermoluminescence personnel dosimetry at Hanford. I. 7 LiF extremity and non-radiation worker dosimeters.

Kocher LF, Kathren RL, Endres GW.

Health Phys. 1970 Apr;18(4):311-7. No abstract available.

PMID:
5513055
18.

A tissue equivalent proportional counter for measuring doses due to neutron radiation. BNWL-1159.

Endres GW, Glass WA, Haverfield AJ.

BNWL Rep. 1969 Jun:7-30. No abstract available.

PMID:
5308911
19.

The response of selected thermoluminescent materials to fast neutron exposures. BNWL-1159.

Endres GW, Kocher LF.

BNWL Rep. 1969 Jun:49-67. No abstract available.

PMID:
5308905
20.

Neutron dosimetry with activation filters and TLD. BNWL-1159.

Kocher LF, Endres GW.

BNWL Rep. 1969 Jun:35-49. No abstract available.

PMID:
5308903
21.

The response of selected thermoluminescent materials to fast neutron exposures. BNWL-1080.

Endres GW, Kocher LF.

BNWL Rep. 1969 Jun:1-16. No abstract available.

PMID:
5308890

Supplemental Content

Loading ...
Support Center